The global cannabis inhaler market is expected to grow at a CAGR of 7.2% between 2023 and 2032.
Cannabis is legally banned in most countries due to its harmful effects, such as extreme addiction. However, in 36 US states, Cannabis is legalized for medicinal and recreational use under the government's set rules and regulations. Cannabis stevia or the cannabis plant contains cannabinoids, natural compounds found quickly in them. The demand for Cannabis inhalers is expected to rise shortly because apart from their side effects on a human’s health, they can help overcome respiratory conditions such as Asthma and COPD, given that it is used under supervision and is well-monitored.
The Cannabis inhaler market is expected to rise shortly because of the high bioavailability of cannabis and the legalization of cannabis in various countries. There is a rise in government initiatives to promote safe and controlled usage of cannabis inhalers; various research projects have been funded to discover more uses of cannabis that might help treat various diseases.
The COVID-19 outbreak was a significant setback to the cannabis inhaler industry as there was a supply of fake medicines, which took away people's confidence in the medical sector, subsequently affecting the cannabis inhalers market.
The lack of awareness on the long-term safety of cannabis used for medicinal purposes can act as a barrier to the profit boundaries in the cannabis inhaler market. In contrast, the changing regulatory outlook and initiatives by the government can act as a boost to the cannabis inhaler market. Asthma is a significant lung disease and potentially hazardous; the asthma segment has generated colossal revenue during the forecast period and has dominated the market.
UK, Germany, and Cyprus have considered cannabis a prescription-based medicinal product, allowing only registered therapeutic practitioners to prescribe it to their patients. Countries such as Sweden, Latvia, Belgium, etc., have put a total ban on Cannabis. This shows the partial acceptance of cannabis inhalers in the European market.
Cannabis for medicinal and recreational purposes is legalized in 36 US states but is banned by federal law due to its residual side effects. The legalization of Cannabis on state levels is a significant boost to the increase in the Cannabis inhalers market in the United States of America.
Key market players
Segmentation of the market
By Application
By Geography
Cannabinoids are natural compounds easily found in the Cannabis Sativa, also known as the Cannabis plant.
The cannabis inhalers market is anticipated to expand at a CAGR of 7.2% from 2023 to 2032.
The cannabis inhalers market is dominated by the North American region.
Vapen Brands, CBD Luxe, Fairwinds Cannabis, Koi CBD, H&T Presspart Manufacturing Ltd., MUV, Syqe Medical Ltd., Monarch Life Sciences LLC, Vectura Group plc among others, are the major players in this market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved